

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Ask Püschl, et al.
Application No.:	10/551,883
Filing or 371(c) Date:	November 29, 2005
Group Art Unit:	1625
Examiner:	Celia C. Chang
For:	4-(2-Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors

December 12, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with Applicants' duty of disclosure under 37 C.F.R. §1.56, transmitted herewith is a Supplemental Information Disclosure Statement (SIDS) to supplement the Information Disclosure Statement filed January 17, 2006, and the Supplemental Information Disclosure Statements filed May 8, 2006 and October 19, 2006, in connection with the above-identified patent application. This SIDS complies with the requirements under 37 C.F.R. § 1.98 and is being submitted pursuant to 37 C.F.R. 1.97(b), wherein the SIDS is being offered within three (3) months of the date of entry of the national stage as set forth in § 1.491 in an international application or before the mailing date of a first Office Action on the merits.

Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, in the event that a first Office Action has been mailed but has not yet been received by Applicants, the Commissioner is hereby authorized to charge any deficiency in fees, or credit overpayment of the same, to Deposit Account No. 503201.

Further, the Examiner's attention is kindly directed to the documents identified on the attached Forms PTO/SB/08. Copies of the U.S. Patents and/or Patent Application Publications are not required pursuant to 37 C.F.R. § 1.98(a)(2)(ii) and, therefore, have not been provided in connection with this submission (Cites A-M). Copies of all other references (Cites N-AAA) are attached.

Applicants respectfully request that the Examiner consider the cited references and that a copy of the enclosed PTO/SB/08 Forms be initialed and returned indicating that such information has been considered. Applicants also respectfully request that the Examiner make the cited references of record in the subject application.

If a telephone conference would be of assistance in advancing the prosecution of the subject application, the undersigned invites the Examiner to telephone her at the number provided below.

Respectfully submitted,

/Stephen G. Kalinchak, Reg. # 38,747/
Stephen G. Kalinchak, Esq.
Registration No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 350-0781 (phone)
(201) 225-9571 (fax)